Targeting HMGB1 in the treatment of sepsis

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 3, 2014, Pages 257-268

  Wang, Haichao ^a   Ward, Mary F ^a   Sama, Andrew E ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antibodies; Cytokines; Herbal component; HMGB1; Innate immune cells; PKR; Sepsis

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; HMGB1 PROTEIN; HUMANS; PHYTOTHERAPY; SEPSIS;

EID: 84894124785     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.863876     Document Type: Review

References (135)

1. Wang H, Zhu S, Zhou R, et al. Therapeutic potential of HMGB1- targeting agents in sepsis. Expert Rev Mol Med 2008;10:e32
2. Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet 2013;381: 774-5 • These authors proposed a new definition for sepsis.
3. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36: 296-327
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-10
5. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005;6: 1182-90
6. Liles WC. Immunomodulatory approaches to augment phagocytemediated host defense for treatment of infectious diseases. Semin Respir Infect 2001;16: 11-17
7. Ha T, Lu C, Liu L, et al. TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide 3-kinase-dependent mechanism. Am J Physiol Heart Circ Physiol 2010;298:H984-91
8. Gao M, Ha T, Zhang X, et al. Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 2012;40: 2390-9
9. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through tolllike receptors. Science 1999;285: 732-6
10. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282: 2085-8
11. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408: 740-5
12. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4: 499-511
13. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000;21: 418-20
14. Chan ED, Riches DW. IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001;280:C441-50
15. Wizemann TM, Gardner CR, Laskin JD, et al. Production of nitric oxide and peroxynitrite in the lung during acute endotoxemia. J Leukoc Biol 1994;56: 759-68
16. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285: 248-51 • These authors made the seminal discovery on the important role of extracellular HMG-1 (now called HMGB1) as a late mediator of lethal systemic inflammation.
17. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330: 662-4 • These authors first reported a pathogenic role of proinflammatory cytokine in the pathogenesis of lethal infection.
18. Chen G, Li J, Qiang X, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005;46: 623-7
19. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22: 5551-60
20. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE 2002;2002:E39
21. Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9- mediated inflammatory responses to CpG-DNA. Blood 2007;110: 1970-81
22. Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488: 670-4 • These authors made a breakthrough progress in uncovering the molecular mechanisms underlying the regulation of HMGB1 release.
23. Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003;170: 3890-7 • These authors first reported the important role of early cytokines in stimulating HMGB1 release.
24. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesiclemediated secretory pathway. EMBO Rep 2002;3: 955-1001
25. Lamkanfi M, Sarkar A, Vande WL, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010;185: 4385-92 • These authors first reported the important role of inflammasome in the regulation of endotoxin-induced HMGB1 release.
26. Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001;276: 3820-6
27. Griffiths RJ, Stam EJ, Downs JT, Otterness IG. ATP induces the release of IL-1 from LPS-primed cells in vivo. J Immunol 1995;154: 2821-8
28. Perregaux DG, McNiff P, Laliberte R, et al. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 2000;165: 4615-23
29. Surprenant A, Rassendren F, Kawashima E, et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996;272: 735-8
30. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418: 191-5 • These authors first reported that HMGB1 can be released by damaged cells.
31. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201: 1135-43 • These authors first reported the extracellular role of HMGB1 as a damage-associated molecular pattern (DAMP) molecule.
32. Qiu J, Nishimura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008;28: 927-38
33. Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemiareperfusion injury of the heart. Circulation 2008;117: 3216-26
34. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009;13:R174
35. Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009;32: 17-22
36. Manganelli V, Signore M, Pacini I, et al. Increased HMGB1 expression and release by mononuclear cells following surgical/anesthesia trauma. Crit Care 2010;14:R197
37. Zhou RR, Liu HB, Peng JP, et al. High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury. Exp Mol Pathol 2012;93: 213-19
38. Takano K, Shinoda M, Tanabe M, et al. Protective effect of high-mobility group box 1 blockade on acute liver failure in rats. Shock 2010;34: 573-9
39. Yang R, Zhang S, Cotoia A, et al. High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol 2012;12: 45
40. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminopheninduced acute liver injury at first presentation to hospital. Hepatology 2013;58: 777-87
41. Seo YS, Kwon JH, Yaqoob U, et al. HMGB1 recruits hepatic stellate cells and liver endothelial cells to sites of ethanol induced parenchymal cell injury. Am J Physiol Gastrointest Liver Physiol 2013; Epub ahead of print
42. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29: 139-62
43. Zhu S, Li W, Ward MF, et al. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 2010;9: 60-72
44. Sursal T, Stearns-Kurosawa DJ, Itagaki K, et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock 2013;39: 55-62
45. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464: 104-7 • These authors first reported that mtDNA functions as a DAMP molecule that orchestrate injuryelicited inflammatory responses.
46. Chen LC, Yeh TM, Wu HN, et al. Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 2008;56: 143-50 • These authors first reported the passive release of HMGB1 from virus infected cells.
47. Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 2008;181: 1454-9
48. Whilding LM, Archibald KM, Kulbe H, et al. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther 2013;21(11): 2074-86
49. Hofner P, Seprenyi G, Miczak A, et al. High mobility group box 1 protein induction by Mycobacterium bovis BCG. Mediators Inflamm 2007;2007: 53805
50. Grover A, Taylor J, Troudt J, et al. Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell Microbiol 2008;10: 1390-404
51. Wang H, Ward MF, Fan XG, et al. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006;19: 3-9
52. Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009;15: 275-82
53. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192: 565-70 • These authors first reported the proinflammatory activities of extracellular HMGB1.
54. Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;81: 59-66 • These authors first reported the chemokine activities of extracellular HMGB1.
55. Dumitriu IE, Bianchi ME, Bacci M, et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007;81: 84-91
56. Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007;26: 1129-39
57. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152: 1197-206
58. Degryse B, de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett 2003;553: 11-17
59. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8: 487-96 • These authors first reported that HMGB1 amplified inflammation by facilitating innate recognition of microbial CpG-DNA.
60. Yu M, Wang H, Ding A, et al. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 2006;26: 174-9
61. Ha T, Xia Y, Liu X, et al. Glucan phosphate attenuates myocardial HMGB1 translocation in severe sepsis through inhibiting NF-kappaB activation. Am J Physiol Heart Circ Physiol 2011;301:H848-55
62. Xiang M, Shi X, Li Y, et al. Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol 2011;187: 4809-17
63. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009;323: 1722-5 • These authors first reported CD24 as another potential cell surface receptor for HMGB1.
64. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group- B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115: 1267-74 • These authors first reported the presence of endogenous HMGB1- binding protein that functions as HMGB1-inhibiting agent.
65. Salmivirta M, Rauvala H, Elenius K, et al. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res 1992;200: 444-51 • These authors first reported the presence of HMGB1 outside of the nucleus (on the cytoplasmic membrane).
66. Park JS, Svetkauskaite D, He Q, et al. Involvement of TLR 2 and TLR 4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem 2004;279: 7370-7
67. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24
68. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61: 1-9
69. Pedrazzi M, Patrone M, Passalacqua M, et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 2007;179: 8525-32
70. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101: 2652-60
71. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003;254: 375-85 • These authors first reported that HMGB1 activates non-immune cells.
72. Kazama H, Ricci JE, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008;29: 21-32
73. Yang H, Lundback P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012;18: 250-9
74. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012;209: 1519-28 • These authors further examined the effects of the redox status of HMGB1 affects its cytokine activities.
75. Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 2012;18: 1360-2
76. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock - A review of laboratory models and a proposal. J Surg Res 1980;29: 189-201
77. Li W, Zhu S, Zhang Y, et al. Use of animal model of sepsis to evaluate novel herbal therapies. J Vis Exp 2012((62)): 3926
78. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101: 296-301 • These authors first reported the extracellular role of HMGB1 as a late mediator of lethal sepsis.
79. Wang H, Yang H, Czura CJ, et al. HMGB1 as a Late Mediator of Lethal Systemic Inflammation. Am J Respir Crit Care Med 2001;164: 1768-73
80. Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165: 2950-4
81. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203: 1637-42
82. Suda K, Kitagawa Y, Ozawa S, et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006;30: 1755-62
83. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23: 1294-303
84. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288: 862-71
85. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358: 111-24
86. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345: 1368-77
87. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358: 877-87
88. Hagiwara S, Iwasaka H, Hasegawa A, et al. High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLPinduced sepsis. Intensive Care Med 2008;34: 1812-19
89. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 2008;34: 361-7
90. Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945
91. Hagiwara S, Iwasaka H, Hasegawa A, et al. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008;36: 2407-13
92. Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by downregulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008;172: 1297-307
93. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting highmobility group box 1 release and by killing bacteria. J Immunol 2008;180: 8369-77
94. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421: 384-8
95. Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med 2004;10: 124-5
96. Hu YM, Pai MH, Yeh CL, et al. Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol 2012;302:F150-8
97. Wang H, Li W, Li J, et al. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006;136: 360-5 • This is the first report showing that herbal extract inhibited HMGB1 release and protected against lethal sepsis.
98. Zhu S, Li W, Li J, et al. It is not just folklore: the aqueous extract of mung bean coat is protective against Sepsis. Evid Based Complement Alternat Med 2012;2012: 498467
99. Jun MS, Kim HS, Kim YM, et al. Ethanol extract of Prunella vulgaris var. lilacina inhibits HMGB1 release by induction of heme oxygenase-1 in LPSactivated RAW 264.7 cells and CLPinduced septic mice. Phytother Res 2012;26: 605-12
100. Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10: 1216-21
101. Li W, Ashok M, Li J, et al. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2007;2:e1153
102. Li W, Li J, Ashok M, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 2007;178: 3856-64
103. Wang W, Zhao F, Fang Y, et al. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care 2013;17:R44
104. Lee CH, Yoon SJ, Lee SM. Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis. Mol Med 2013;18: 1437-48
105. Lee W, Ku SK, Kim TH, Bae JS. Emodin-6-O-beta-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol 2013;52: 97-104
106. Yang EJ, Ku SK, Lee W, et al. Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. J Cell Physiol 2013;228: 975-82
107. Kim TH, Ku SK, Bae JS. Anti-inflammatory activities of isorhamnetin-3-O-galactoside against HMGB1-induced inflammatory responses in both HUVECs and CLPinduced septic mice. J Cell Biochem 2013;114: 336-45
108. Kim TH, Ku SK, Bae JS. Persicarin is anti-inflammatory mediator against HMGB1-induced inflammatory responses in HUVECs and in CLPinduced sepsis mice. J Cell Physiol 2013;228: 696-703
109. Jiang WL, Yong X, Zhang SP, et al. Forsythoside B protects against experimental sepsis by modulating inflammatory factors. Phytother Res 2012;26: 981-7
110. Yang M, Cao L, Xie M, et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol 2013;86(3): 410-18
111. Seo ES, Oh BK, Pak JH, et al. Acteoside improves survival in cecal ligation and puncture-induced septic mice via blocking of high mobility group box 1 release. Mol Cells 2013;35: 348-54
112. Li W, Zhu S, Li J, et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxinstimulated macrophages. Biochem Pharmacol 2011;81: 1152-63
113. Zhang Y, Li W, Zhu S, et al. Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. Biochem Pharmacol 2012;84: 1492-500
114. Lu B, Wang H, Andersson U, et al. Regulation of HMGB1 release by inflammasomes. Protein Cell 2013;4: 163-7
115. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr 1998;128: 2334-40
116. Ichikawa D, Matsui A, Imai M, et al. Effect of various catechins on the IL- 12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biol Pharm Bull 2004;27: 1353-8
117. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006;177: 1967-74
118. Heuer JG, Sharma GR, Gerlitz B, et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med 2004;32: 1570-8
119. Li W, Li J, Sama AE, et al. Carbenoxolone Blocks Endotoxin- Induced Protein Kinase R (PKR) Activation and High Mobility Group Box 1 (HMGB1) Release. Mol Med 2013;19: 203-11
120. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA- 1A Sepsis Study Group. N Engl J Med 1991;324: 429-36
121. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/ permeabilityincreasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356: 961-7
122. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309: 1154-62
123. Hagar JA, Powell DA, Aachoui Y, et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013;341: 1250-3 • These authors first reported a TLR4- independent cytoplasmic signaling pathway for endotoxin-mediated inflammasome activation and cytokine release.
124. Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013;341: 1246-9 • These authors first reported a cytoplasmic signaling pathway involved in endotoxin-mediated inflammasome activation and cytokine release.
125. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229: 869-71 • These authors first reported a pathogenic role of TNF in lethal endotoxemia.
126. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273: 934-41
127. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19: 163-96
128. Zhang Y, Yao YM, Huang LF, et al. The potential effect and mechanism of highmobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 2011;31: 249-57
129. Wild CA, Bergmann C, Fritz G, et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 2012;24: 485-94
130. Aneja RK, Tsung A, Sjodin H, et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 2008;84: 1326-34
131. Robert SM, Sjodin H, Fink MP, et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipoteichoic acid (LTA) tolerance. J Immunother 2010;33: 663-71
132. Entezari M, Weiss DJ, Sitapara R, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18: 477-85 • These author first reported the extracellular role of HMGB1 in the impairment of bacterial elimination by macrophages.
133. Patel VS, Sitapara RA, Gore A, et al. High Mobility Group Box-1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory lung injury in mice. Am J Respir Cell Mol Biol 2013;48: 280-7
134. Liu G, Wang J, Park YJ, et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 2008;181: 4240-6
135. Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 2000;21: 1089-94